About us

Founded under the leadership of CEO John Ruprai in the United Kingdom, Ennogen stands as a pharmaceutical enterprise specializing in an extensive array of medicines and medical devices, with a predominant focus on therapeutic areas such as respiratory and dermatology. This commitment is further underscored by our robust portfolio, encompassing both generic medicines and proprietary formulations.

Since its inception, Ennogen has demonstrated a steadfast commitment to innovation and regulatory compliance, resulting in the development of a differentiated portfolio with over 150 Market Authorisations. This diverse range of approvals positions us as a strong presence in the pharmaceutical landscape, granting us a comprehensive commercial coverage that spans the entirety of the UK mainline and shortline wholesale channels. Our reach extends beyond traditional distribution channels, encompassing private and National Health Service (NHS) hospitals, community and retail pharmacies, as well as collaboration with Clinical Commissioning Groups.

Notably, Ennogen has garnered acclaim as a preferred choice among pharmacists and clinicians, a testament to our unwavering dedication to delivering high-quality and affordable pharmaceutical products. Our success in meeting the demands of healthcare professionals has facilitated our expansion into local, national, and international markets. We take pride in conducting our operations with the utmost ethical standards, efficiency, and professionalism, solidifying our standing as a reliable and reputable pharmaceutical provider.